The DOI matches its Crossref record; the references it cites are not checked yet.
The novel mechanism of lenalidomide activity
Open accessAbstract
Lenalidomide acts by a novel drug mechanism—modulation of the substrate specificity of the CRL4CRBN E3 ubiquitin ligase. In multiple myeloma, lenalidomide induces the ubiquitination of IKZF1 and IKZF3 by CRL4CRBN. Subsequent proteasomal degradation of these transcription factors kills multiple myeloma cells. In del(5q) myelodysplastic syndrome, lenalidomide induces the degradation of CK1α, which preferentially affects del(5q) cells because they express this gene at haploinsufficient levels. In the future, modulation of ubiquitin ligase function may enable us to target previously “undruggable” proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide and its derivatives, lenalidomide and pomalidomide, are effective therapies for the hematologic malignancies multiple myeloma, del(5q) myelodysplastic syndrome, and mantle cell lymphoma (1).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IKZF1, IKZF3 and CK1α are required for MM or MDS cell survival (BOX 2)”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“thereby establishing selective degradation of disease-relevant proteins as the unexpected mechanism underlying the anticancer effects of thalidomide analogues16.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 35 · Cited by 213
Metadata
- Authors
- Fink, E. C., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2015-11-19
- Volume
- 126
- Issue
- 21
- Pages
- 2366-2369
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC4653765
- OpenAlex
- W2216031179
- Cited by
- 213
- References
- 35
- Citations by year
- 2026: 20 · 2025: 28 · 2024: 17 · 2023: 22 · 2022: 18 · 2021: 33 · 2020: 19 · 2019: 18 · 2018: 12 · 2017: 16 · 2016: 9
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- Celgene
- Commonwealth Health Research Board
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL082945)
- National Cancer Institute (F30CA199988, P01CA108631)
- National Institute of General Medical Sciences (T32GM722639, T32GM007753, T32GM007226)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, IKZF1, IKZF3, CK1α, multiple myeloma, del(5q) myelodysplastic syndrome, ubiquitination, proteasomal degradation, transcription factor degradation, drug mechanisms, undruggable proteins
- MeSH terms
- Lenalidomide, Animals, Humans, Multiple Myeloma, Myelodysplastic Syndromes, Thalidomide, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Ikaros Transcription Factor, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The novel mechanism of lenalidomide activity. https://app.cochat.ai/papers/10.1182/blood-2015-07-567958
- The paper
- Fink, E. C., & Ebert, B. L. (2015). The novel mechanism of lenalidomide activity. Blood. https://doi.org/10.1182/blood-2015-07-567958
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.